COVID-19 Updates: Latest Information for Parents
Rady Children's Specialists

Allergy & Immunology

Active Clinical Trials

Peanut Allergy Patch Trial in Young Children (EPITOPE)

Principal Investigator: Dr. Stephanie Leonard

This is a study designed to determine if an investigational skin patch is safe and effective when used as epicutaneous immunotherapy for peanut allergy in young children. If your child is between 1-3 years old and is allergic to peanut, he/she may be eligible to participate. Please contact Amy Grissinger, CPNP, at agrissinger@rchsd.org for more information. https://clinicaltrials.gov/ct2/show/NCT03211247

Microbiome, Atopy and Prematurity (MAP) study

Principal Investigators: Drs. Sydney Leibel and Bob Geng

This is a study designed to determine the role of the microbiome in the development of allergic conditions in those with a history of prematurity. If your child is between 3-6 years old, has a history of prematurity (less than 36wks gestation) and has asthma, he/she may be eligible to participate. Those without a history of asthma may also qualify as a control group. Please contact Dr. Jessica Galant-Swafford at jgalantswafford@health.ucsd.edu for more information.

Preventing Asthma in High-Risk Kids (PARK) study

Principal Investigators: Drs. Sydney Leibel and Bob Geng

A study designed to test whether two years treatment of preschool children aged 2-3 years of age at high risk for asthma with omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as reflected by a reduction in the prevalence of active asthma in the Final 12 months during 2 year observation period off study drug. If your child is between 2-3 years old, has wheezing, and a family history of asthma or allergies, he/she may be eligible to participate. Please contact Diba Mortazavi, at dmortazavi@ucsd.edu for more information. https://clinicaltrials.gov/ct2/show/NCT02570984

IL-18 Binding Protein (Tadekinig) in Pediatric Patients with NLRC4 and XIAP1 

Principal Investigator: Dr. Hal Hoffman

This is a study designed to determine if an investigational drug is safe and effective in patients 17 years old and under with NLRC4 and XIAP1 mutations.

Please contact Dr. Hal Hoffman at hhoffman@rchsd.org for more information. 

https://clinicaltrials.gov/ct2/show/NCT03113760?cond=nlrc4&draw=2&rank=1

Characteristics and Inflammatory Markers in Children With Eosinophilic Esophagitis (EoE)

Principle Investigator: Dr. Seema Aceves

Database and sample collection study

Please contact Kira Chaiboonma at kchaiboonma@health.ucsd.edu for more information.

https://clinicaltrials.gov/ct2/show/NCT03980886

Somatization, Anxiety and Disordered Sleep in Pediatric Eosinophilic Esophagitis 

Principle Investigator: Dr. Seema Aceves

To understand the symptoms and severity of anxiety, disordered sleep and somatization and how these parameters align with symptoms and quality of life in pediatric EoE.

Please contact Kira Chaiboonma at kchaiboonma@health.ucsd.edu for more information.

https://clinicaltrials.gov/ct2/show/NCT04309786

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE), Multicenter

Sponsor: Regeneron Pharmaceuticals

Principle Investigator: Dr. Seema Aceves

To evaluate the safety, tolerability and immunogenicity of dupilumab treatment for up to 52 weeks in adult and adolescent patients with EoE

To explore the relationship between dupilumab concentration and responses in adult and adolescent patients with EoE, using descriptive analyses

https://clinicaltrials.gov/ct2/show/NCT03633617

OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA)

Principle Investigator: Dr. Seema Aceves

To find the best measures to define how well a person with eosinophilic disorder is doing.

Please contact Kira Chaiboonma at kchaiboonma@health.ucsd.edu for more information.

https://clinicaltrials.gov/ct2/show/NCT02523118